Fig. 4From: Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort studyKaplan-Meier curves of overall survival in the first-line gemcitabine group, S-1 group, and gemcitabine plus nab-paclitaxel group (a); and progression-free survival in the first-line gemcitabine group, S-1 group, and gemcitabine plus nab-paclitaxel group (b). OS, overall survival; PFS, progression-free survivalBack to article page